Zeaxanthin

ID85
NameZeaxanthin
Synonymsall-trans-Zeaxanthin
StructureThumb
DescriptionCan coelute with lutein.
GroupCarotenoids
Sub-groupXanthophylls
Exposure sourceDiet
Use
CAS number144-68-3
PubChem ID5280899
ChEBI ID27547
FooDB IDFDB019865
HMDB IDHMDB02789

Biomarker measurements

Biomarker concentration values

IDParent IDDepthSubject groupPopulationCountryCountry codeCohortTime definitionBiospecimenAnalytical methodBiomarkerBiomarker detailMeasurement sizeDetected (nb)Detected (%)Detected only?Arithmethic meanArithmethic SDGeometric meanGeometric SDMinMin (detected)Percentile_05Percentile_10Percentile_25MedianPercentile_75Percentile_90Percentile_95MaxInterquartile rangeMean 95% CI lowerMean 95% CI upperGMean 95% CI lowerGMean 95% CI upperUnitConverted arithmetic meanConverted geometric meanConverted medianAdjustment typeAdjusted onRegressed onExpressed asPublication
239924001Sub-study IParticipants in a dietary validation studyNorwayNOPlasma, fastingHPLCZeaxanthin14728.039.053.0nmol/L39.0 nmol/LCrudeCarlsen 2011
242024211Sub-study IIParticipants in a dietary validation studyNorwayNOPlasma, fastingHPLCZeaxanthin8529.039.051.0nmol/L39.0 nmol/LCrudeCarlsen 2011
256625642AllGeneral adult population in BostonUnited StatesUSSerum, fastingHPLCZeaxanthin2534.4nmol/L34.4 nmol/LCrudeChung 2009
258325812AllGeneral adult population in BostonUnited StatesUSAdipose tissue, abdomenHPLCZeaxanthin25183.4pmol/mg0.2 umol/gDensitySpecimen dry weightChung 2009
260226002AllGeneral adult population in BostonUnited StatesUSAdipose tissue, buttocksHPLCZeaxanthin25127.5pmol/mg0.1 umol/gDensitySpecimen dry weightChung 2009
262026182AllGeneral adult population in BostonUnited StatesUSAdipose tissue, thighHPLCZeaxanthin25101.0pmol/mg0.1 umol/gDensitySpecimen dry weightChung 2009
399540001MalesParticipants in the EPIC calibration study from nine European countriesFranceFREPIC (European Prospective Investigation into Cancer and Nutrition)Plasma, unspecifiedHPLCZeaxanthin15170.09umol/L90.0 nmol/LCrudeAl-Delaimy 2005
400240071FemalesParticipants in the EPIC calibration study from nine European countriesFranceFREPIC (European Prospective Investigation into Cancer and Nutrition)Plasma, unspecifiedHPLCZeaxanthin15170.09umol/L90.0 nmol/LCrudeAl-Delaimy 2005
40730All [by gender]Subjects from Golestan ProvinceIran, Islamic Republic ofIRGCS (Golestan Cohort Study)Serum, unspecifiedHPLCZeaxanthin1170.0530.02umol/L53.0 nmol/LCrudeMalekshah 2006
40800All [by gender]Subjects from Golestan ProvinceIran, Islamic Republic ofIRGCS (Golestan Cohort Study)Serum, unspecifiedHPLCZeaxanthin1170.0680.04umol/L68.0 nmol/LCrudeMalekshah 2006
44190AllType I diabetic patientsSpainESSerum, fastingHPLCZeaxanthin400.070.03umol/L70.0 nmol/LCrudeGranado-Lorencio 2006
46240AllMen from Oerland military flight stationNorwayNOSerum, fastingHPLCZeaxanthin1000.0390.0150.038umol/L39.0 nmol/L38.0 nmol/LCrudeAndersen 2005
469747033MalesAdultsNetherlandsNLMORGEN-EPIC projectPlasma, non-fastingHPLCZeaxanthin2840.0660.028umol/L66.0 nmol/LCrudeJansen 2004
470947153FemalesAdultsNetherlandsNLMORGEN-EPIC projectPlasma, non-fastingHPLCZeaxanthin2870.0850.034umol/L85.0 nmol/LCrudeJansen 2004
726372972AllWomen in the southern part of Mexico CityMexicoMXPlasma, non-fastingHPLCZeaxanthin11073.130.1ug/L0.1 mg/LCrudeRomieu 1999
92340All [HPFS]Men living in the Boston areaUnited StatesUSHPFS (Health Professionals Follow-Up Study)Plasma, non-fastingHPLCZeaxanthin1210.070.03umol/L70.0 nmol/LCrudeAscherio 1992
92440All [NHS]Women living in the Boston areaUnited StatesUSNHS (Nurses' Health Study)Plasma, non-fastingHPLCZeaxanthin1860.060.03umol/L60.0 nmol/LCrudeAscherio 1992
18252182532AllHawaii womenUnited StatesUSCohort study of cervical human papillomavirus at the Cancer Research Center of Hawaiibaseline; month 4; month 8; month 12Plasma, fastingHPLCZeaxanthin38164.028.00.058.0281.0ng/mL0.1 mg/L0.1 mg/LCrudeShvetsov 2009

Intake values

IDParent IDDepthSubject groupPopulationCountryCountry codeCohortTime definitionIntake toolIntake food coverageIntake time coverageIntake assessmentCompoundCompound detailSupplement intakes included?Measurement sizeDetected (nb)Detected (%)Detected only?Arithmethic meanArithmethic SDGeometric meanGeometric SDMinMin (detected)Percentile_05Percentile_10Percentile_25MedianPercentile_75Percentile_90Percentile_95MaxInterquartile rangeMean 95% CI lowerMean 95% CI upperGMean 95% CI lowerGMean 95% CI upperUnitConverted arithmetic meanConverted geometric meanConverted medianAdjustment typeAdjusted onRegressed onExpressed asPublication
44250AllType I diabetic patientsSpainESFood Frequency Questionnaire (FFQ)Zeaxanthin40110.091.0ug/day0.1 mg/dayCrudeGranado-Lorencio 2006
44310AllType I diabetic patientsSpainESDietary record (3-day)Zeaxanthin4097.0106.0ug/day0.1 mg/dayCrudeGranado-Lorencio 2006

Correlation values

Reproducibility values

IDMst. IDSubject groupPopulationCountryCountry codeCohortTime definitionBiological specimenExperimental methodBiomarkerBiomarker detailArithmetic meanGeometric meanMedianUnitAdjusted onReproducibility sizeICCICC 95% CI lowerICC 95% CI upperCV% WSCV% BSVAR WSVAR BSPublication
18718497AllWomenUnited StatesUSNYUWHS (New York University Women's Health Study)baseline; 1 year; 2 yearsSerum, non-fastingHPLCZeaxanthinmissing unit480.63van Kappel 2001
10818252AllHawaii womenUnited StatesUSCohort study of cervical human papillomavirus at the Cancer Research Center of Hawaiibaseline; month 4; month 8; month 12Plasma, fastingHPLCZeaxanthin64.058.0ng/mL3810.640.0020.003Shvetsov 2009
61919090AllDutch participants of the EPIC-StudyNetherlandsNLMORGEN-EPIC projectbaseline; 3 yearsPlasma, non-fastingHPLCZeaxanthinnmol/L620.370.170.53Leenders 2013